Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To determine in subjects with Type 1 Diabetes Mellitus:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Inhaled human insulin | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| Primary outcome is 24 week change in baseline in HbA1c. |
| Measure | Description | Time Frame |
|---|---|---|
| The secondary endpoints include the following efficacy assessments: | ||
| Incidence of hypoglycemia | ||
| Proportion of subjects with acceptable glycemic control (e.g., HbA1c<8%) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | Duarte | California | United States | |||
| Pfizer Investigational Site |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Change from baseline in fasting lipid profile |
| Change from baseline in fasting plasma glucose level |
| Change from baseline in meal glucose response (2-hour postprandial increment in plasma glucose) |
| Dose of insulin (total dose of injected sustained-duration insulin, and total dose of inhaled or injected Regular insulin during the study). |
| Change from baseline in body weight |
| Change from baseline in 24-hour home glucose profile (based on the area under the glucose profile curve calculated by the trapezoid rule with special weights assigned to the pre-breakfast and bedtime assessments). |
| Patient satisfaction and preference. |
| Long Beach |
| California |
| United States |
| Pfizer Investigational Site | Los Angeles | California | United States |
| Pfizer Investigational Site | Stanford | California | United States |
| Pfizer Investigational Site | Denver | Colorado | United States |
| Pfizer Investigational Site | New Haven | Connecticut | United States |
| Pfizer Investigational Site | Gainesville | Florida | United States |
| Pfizer Investigational Site | Hollywood | Florida | United States |
| Pfizer Investigational Site | Miami | Florida | United States |
| Pfizer Investigational Site | Tallahassee | Florida | United States |
| Pfizer Investigational Site | Peoria | Illinois | United States |
| Pfizer Investigational Site | Skokie | Illinois | United States |
| Pfizer Investigational Site | Lutherville | Maryland | United States |
| Pfizer Investigational Site | Waltham | Massachusetts | United States |
| Pfizer Investigational Site | Minneapolis | Minnesota | United States |
| Pfizer Investigational Site | Columbia | Missouri | United States |
| Pfizer Investigational Site | New Hyde Park | New York | United States |
| Pfizer Investigational Site | Rochester | New York | United States |
| Pfizer Investigational Site | Syracuse | New York | United States |
| Pfizer Investigational Site | The Bronx | New York | United States |
| Pfizer Investigational Site | Durham | North Carolina | United States |
| Pfizer Investigational Site | Winston-Salem | North Carolina | United States |
| Pfizer Investigational Site | Portland | Oregon | United States |
| Pfizer Investigational Site | Pittsburgh | Pennsylvania | United States |
| Pfizer Investigational Site | Dallas | Texas | United States |
| Pfizer Investigational Site | Houston | Texas | United States |
| Pfizer Investigational Site | Burlington | Vermont | United States |
| Pfizer Investigational Site | Charlottesville | Virginia | United States |
| Pfizer Investigational Site | Charlottsville | Virginia | United States |
| Pfizer Investigational Site | Seattle | Washington | United States |
| Pfizer Investigational Site | Edmonton | Alberta | Canada |
| Pfizer Investigational Site | Hamilton | Ontario | Canada |
| Pfizer Investigational Site | Mississauga | Ontario | Canada |
| Pfizer Investigational Site | Toronto | Ontario | Canada |
| Pfizer Investigational Site | Montreal | Quebec | Canada |
| ID | Term |
|---|---|
| D003922 | Diabetes Mellitus, Type 1 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
Not provided
Not provided